Clinical Trials Directory

90Y-Ibritumomab Tiuxetan and Autologous Hematopoietic Cell Infusion Followed by High Dose Chemotherapy and Autologous Transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma

To test a new way to approach hematopoietic stem cell transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : 90Y Ibritumomab tiuxetan

Phase: Phase 1


Ages Eligible For Study:

18 Years - 70 Years

Inclusion Criteria

Inclusion Criteria -- Step 1 4.1 Histologically proven, recurrent or refractory, CD20+ B-cell NHL reviewed at SUMC. 4.11 The definition of recurrent disease is: previous partial response (PR) or complete response (CR) to treatment followed by disease progression. 4.12 The definition of refractory disease is: failure to achieve a PR or CR with or progression during primary induction therapy or subsequent salvage therapy. Patients who respond to treatment but progress within 60 days will also be considered refractory. 4.13 CD20 expression may be determined by immunohistochemistry or flow cytometry. Whenever possible, confirmation of CD20+ status should be made on current, active disease. 4.14 The definition of NHL will be made by SUMC pathologists using the World Health Organization Classification of Hematopoietic and Lymphoid Tissues (Appendix A). 4.15 The diagnosis should be made by excisional biopsy whenever possible. Biopsy of refractory or recurrent disease is preferred but fine needle aspirate with supportive morphology and immunohistochemistry is acceptable. Paraffin tissue for tissue array studies will be sought for every patient. 4.2 Age 18-70 years 4.21 Age will be based on actual date of birth. 4.22 Pediatric patients are not eligible for this study because they are transplanted in a separate dedicated unit with their own protocols. 4.3 ECOG performance status 0-2 (Appendix B) 4.4 Computerized tomography scans of the chest, abdomen and pelvis within 4 weeks of registration. Assessment of response to last chemotherapy prior to registration is mandatory. 4.41 Response will be assessed according to the international consensus criteria (Cheson et al. J Clin Oncol 17:1244, 1999) 4.42 Standard definitions of the chest, abdomen and pelvis will be used for radiographic studies. 4.5 Gallium scan or PET scan determination of disease within 4 weeks of registration is highly recommended. 4.51 Gallium or PET scans will be whole body scans 4.6 Bone marrow biopsy and cytogenetic analysis within 8 weeks of registration. Patients must have no or <25% involvement of the intratrabecular bone marrow cellularity by NHL. 4.7 Adequate (> 4 x 10^6/kg CD34+) peripheral blood progenitor cells collected by apheresis. 4.8 Women of child-bearing potential and sexually active males are strongly advised to use an accepted and effective method of birth control. 4.9 No chemotherapy other than corticosteroids should be administered within 4 weeks of the initiation of protocol therapy. 4.10 Pretreatment absolute neutrophil count > 1000/mm^3 and platelet count > 150,000/ mm^3. 4.11 Patients must have a pretreatment serum bilirubin < 2 x the institutional ULN, transaminases < 2 x the institutional ULN, a serum creatinine < 2 x the institutional ULN and measured or estimated creatinine clearance > 60 cc/min by the following formula (all tests must be performed within 28 days prior to registration): Estimated Creatinine Clearance = (140 age)X WT(kg) X 0.85 if female X creatinine (mg/dl) 4.12 Patients must have an EKG within 42 days prior to registration that shows no significant abnormalities that are suggestive of active cardiac disease. 4.13 Patients must have a radionuclide ejection fraction >45% within 42 days of registration. 4.14 Patients must have a corrected diffusion capacity 70% or greater. 4.15 Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. Inclusion Criteria -- Step 2 4.30 Absolute neutrophil count recovery to > 1000/mm^3 and platelet recovery count to > 100,000/ mm^3. 4.31 Corrected diffusing capacity > 60%. 4.32 Resting ejection fraction of > 45%. 4.33 Serum bilirubin < 2, SGOT (AST) < 2 x ULN, SGPT (ALT) < 2 x ULN. Creatinine < 2 x the ULN and measured or estimated creatinine clearance > 60 cc/min.

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
Not Recruiting

Footer Links: